Video

Dr Shah on the Investigation of LV20.19 CAR in MCL

Nirav N. Shah, MD, discusses the investigation of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Nirav N. Shah, MD, associate professor, Medical College of Wisconsin, discusses the investigation of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens (LV20.19 CAR) in patients with relapsed or refractory mantle cell lymphoma (MCL).

Investigators previously launched a phase 1/2 trial (NCT04186520) that aimed to investigate LV20.19 CAR in patients with relapsed/refractory B-cell malignancies, including MCL, Shah begins. Previously, investigators had completed the phase 1 portion of the trial, which that led to a promising overall response rate (ORR) and allowed investigators identify an appropriate dose level of LV20.19 CAR, Shah says.

A single-center pilot study was designed from the phase 1/2 trial to further investigate LV20.19 CAR in patients with MCL Within this portion of the study, investigators specifically studied patients with MCL as a pilot clinical trial, Shah adds. Findings presented at the 2023 Transplantation & Cellular Therapy Meetings showed that LV20.19 elicited a 90-day complete response (CR) rate of 92% in patients with relapsed/refractory MCL. Additionally, At day 28, the ORR was 100%, and 71% of patients achieved a CR.

MCL was selected for this study because it is a unique non-Hodgkin lymphoma that is known for high levels of CD20 expression, Shah continues. Since agents such as rituximab (Rituxan) have been shown to produce a survival benefit in MCL, it was thought that LV20.19 CAR could benefit patients with MCL since it targets both CD19 and CD20, Shah concludes.

Related Videos
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD
Massimo Cristofanilli, MD, attending physician, NewYork-Presbyterian Hospital; professor, medicine, Weill Cornell Medical College, Cornell University
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Ajay K. Nooka, MD, MPH, FACP